Comparing chair time required for systemic agent drug reaction (DR) management to allocated chair time for systemic protocol. Issue 28 (1st October 2022)
- Record Type:
- Journal Article
- Title:
- Comparing chair time required for systemic agent drug reaction (DR) management to allocated chair time for systemic protocol. Issue 28 (1st October 2022)
- Main Title:
- Comparing chair time required for systemic agent drug reaction (DR) management to allocated chair time for systemic protocol.
- Authors:
- Rauw, Jennifer Marie
Anderson, Helen
Parimi, Sunil
Brown, Michelle
Hennessy, Kathleen - Abstract:
- Abstract : 40 Background: Chemotherapy scheduling and determining associated nursing resources are complex multiobjective decision problems. Management of DRs are thought to take additional chair and nurse time and should be accounted for in appointment scheduling in order to having an efficiently running clinic. BC Cancer – Victoria is a tertiary care regional site of BC Cancer in Victoria, British Columbia, Canada and currently schedules patients using a regimen-based resource intensity model (Greene et al, 2012). Methods: DRs were tracked in real time over 3 months, where BC Cancer ID, reaction, protocol, agent, cycle number and time of reaction were recorded. Our electronic medical record was interrogated to determine start and end of chair time. We then compared the actual chair time required to manage patients with a DR to scheduled chair time. Results: Thirty reactions occurred, including DRs to paclitaxel (43%), rituximab (13%), docetaxel (10%), nivolumab (7%), oxaliplatin (7%), pertuzumab (7%), bendmustine (3%), and daratumumab (3%). The reactions most commonly occurred with cycles 1 or 2. The averages for total chair time during DR, time from arrival to reaction, and time from reaction to discharge were 281 min (+79.5), 106 min (+ 55), and 171 min (+ 94), respectively. An average of 449 min/month extra were required for DR management above scheduled chair time. Conclusions: The agents precipitating DRs were common and predictable. An average of 7 hours and 29Abstract : 40 Background: Chemotherapy scheduling and determining associated nursing resources are complex multiobjective decision problems. Management of DRs are thought to take additional chair and nurse time and should be accounted for in appointment scheduling in order to having an efficiently running clinic. BC Cancer – Victoria is a tertiary care regional site of BC Cancer in Victoria, British Columbia, Canada and currently schedules patients using a regimen-based resource intensity model (Greene et al, 2012). Methods: DRs were tracked in real time over 3 months, where BC Cancer ID, reaction, protocol, agent, cycle number and time of reaction were recorded. Our electronic medical record was interrogated to determine start and end of chair time. We then compared the actual chair time required to manage patients with a DR to scheduled chair time. Results: Thirty reactions occurred, including DRs to paclitaxel (43%), rituximab (13%), docetaxel (10%), nivolumab (7%), oxaliplatin (7%), pertuzumab (7%), bendmustine (3%), and daratumumab (3%). The reactions most commonly occurred with cycles 1 or 2. The averages for total chair time during DR, time from arrival to reaction, and time from reaction to discharge were 281 min (+79.5), 106 min (+ 55), and 171 min (+ 94), respectively. An average of 449 min/month extra were required for DR management above scheduled chair time. Conclusions: The agents precipitating DRs were common and predictable. An average of 7 hours and 29 minutes per month above scheduled chair time was required to manage DRs. This information could be used to more efficiently schedule chair and nursing time. This also highlights the need to minimize the number of DRs as management is resource intensive.Agent Average Cycle number DR occurred at Total Chair Time allocated per protocol (min) Average Actual Total Chair Time (min) Average Actual Reaction to Discharge Chair Time (min) Paclitaxel 1.1 180-300 288 (+93.5) 219 (+79) Rituximab 1.3 90-420 332(+58) 252 (+ 99) Docetaxel 1.25 90-180 273(+49) 169 (+18) … (more)
- Is Part Of:
- Journal of clinical oncology. Volume 40:Issue 28(2022)Supplement
- Journal:
- Journal of clinical oncology
- Issue:
- Volume 40:Issue 28(2022)Supplement
- Issue Display:
- Volume 40, Issue 28 (2022)
- Year:
- 2022
- Volume:
- 40
- Issue:
- 28
- Issue Sort Value:
- 2022-0040-0028-0000
- Page Start:
- 40
- Page End:
- 40
- Publication Date:
- 2022-10-01
- Subjects:
- 130-495
2
78 -- 69 -- 256 -- 14 -- 239 -- 151 -- 301
2 -- 2 -- 2 -- 1 -- 1 -- 1 -- 1
Oncology -- Periodicals
Cancer -- Periodicals
Oncology
Medical Oncology
Cancérologie -- Périodiques
Cancer -- Périodiques
Cancérologie
Cancer
Oncology
Oncologia
Càncer
Periodicals
616.994 - Journal URLs:
- http://www.jco.org/ ↗
http://jco.ascopubs.org/ ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1200/JCO.2022.40.28_suppl.040 ↗
- Languages:
- English
- ISSNs:
- 0732-183X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24579.xml